Transfusion-related non-A, non-B hepatitis in elective spine deformity surgery patients in Gothenburg, Sweden.
This study presented a retrospective analysis of the incidence and clinical course of non-A, non-B hepatitis in patients after receiving homologous blood transfusion for elective spine deformity surgery, at Sahlgren Hospital. The medical records of all patients who underwent surgical procedures for scoliosis and spondylolisthesis between January 1, 1971 and December 31, 1986 were reviewed. From this group, 918 patients with negative medical histories for prior homologous blood transfusion, hepatitis, or the exposure to hepatotoxic medications were selected. All of the patients received two or more units of homologous blood and were followed for at least 1 year postoperatively. Eight hundred fifty-nine (94%) of the patients were either personally interviewed or contacted by mail. The group included 697 scoliosis patients (average age 16.2) and 162 spondylolisthesis patients (average age, 16.8). The scoliosis and spondylolisthesis patients received an average of 5.6 and 3.4 units of homologous blood, respectively. Three patients (0.35%) developed posttransfusion hepatitis, all non-A non-B. The incubation period was 9 to 12 weeks. Presenting symptoms varied widely, ranging from no symptoms to marked icterus. Two of the three patients went on to develop chronic persistent hepatitis, which was confirmed by liver biopsy. The incidence identified in this retrospective study was low when compared with an overall incidence of 4 to 15%, as presented in several larger prospective studies. Non-A, non-B hepatitis is a major risk associated with the homologous transfusion of blood and must be considered one of the more serious complications in surgery for spinal deformity.